La chaîne d'options affiche les données clés des options sur actions de Enanta Pharma à différents prix d'exercice et dates d'expiration. Les traders utilisent ces informations pour analyser les transactions potentielles et évaluer le sentiment du marché pour Enanta Pharma..

Enanta Pharma (NASDAQ:ENTA) Stock, Chaîne d'Options

ENANTA PHARMACEUTICALS INC

Enanta Pharma

Enanta Pharmaceuticals Inc is an American biotechnology company which uses robust, chemistry-driven approach and drug discovery capabilities to focus on the research and development of molecule drugs to cure viral infections and liver diseases. Uses virology and immunology method for curing the diseases. The targeted diseases are hepatitis C, hepatitis B, nonalcoholic steatohepatitis, and the respiratory syncytial virus. The novelty of company research is a specific direct-acting antiviral inhibitor against the hepatitis C virus. The company's inhibitors have been developed in collaboration with AbbVie. AbbVie markets the protease inhibitor, paritaprevir, while other inhibitors are in the pipeline.

Enanta Pharmaceuticals, Inc. - Common Stock

Enanta Pharmaceuticals Inc

Entain PLC

Editor's Note: This headline and story have been updated to clarify that the FDA approval was for an expanded indication to treat acute HCV.
The U.S. Food and Drug Administration (FDA) approved a label expansion for AbbVie Inc's (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ABBV#NYSE">ABBV</a>) Mavyret (glecaprevir/pibrentasvir) to include treatment of acute hepatitis C virus (HCV) infection in patients without cirrhosis <a href="https://www.benzinga.com/general/health-care">or with compensated cirrhosis.</a>
Glecaprevir, one of the two DAAs in Mavyret, was Discovered by Enanta Pharmaceuticals, Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ENTA#NASDAQ">ENTA</a>) and developed and commercialized by AbbVie.
Also Read: <a href="https://www.benzinga.com/25/05/45621885/abbvie-highlights-cancer-trial-data-presentation-at-upcoming-asco-annual-meeting" target="_blank" rel="noreferrer noopener">AbbVie To Present Cancer Trial Data At Upcoming ASCO Event</a>
With this approval, Mavyret is the first and only DAA therapy approved to treat patients with acute HCV in eight weeks with a 96% cure rate.
HCV is a highly infectious blood-borne <a target="_blank" href="https://www.benzinga.com/pressreleases/25/06/n45889177/u-s-fda-approves-expanded-indication-for-abbvies-mavyret-glecaprevirpibrentasvir-as-first-and-only" rel="noreferrer noopener">disease affecting the liver</a>.
The United States&nbsp;is expected to incur&nbsp;around $120 billion&nbsp;in total medical costs over the next 10 years through 2035 linked to chronic liver disease and other related conditions caused by untreated HCV.
Data from the Phase 3, multicenter, single-arm prospective study evaluating the safety and efficacy of Mavyret eight-week treatment in adults with acute HCV infection supported the label expansion.
The study results showed Mavyret to be a highly efficacious treatment for people with acute HCV.
The majority of the adverse events reported were mild or moderate in severity. Fatigue, asthenia, headache, and diarrhea were the most common adverse events.
In 2017, the FDA approved Mavyret to <a target="_blank" href="https://news.abbvie.com/2019-09-26-AbbVie-Receives-FDA-Approval-of-MAVYRET-R-glecaprevir-pibrentasvir-to-Shorten-Treatment-Duration-to-Eight-Weeks-for-Treatment-Naive-Patients-with-Chronic-Hepatitis-C-and-Compensated-Cirrhosis-Across-All-Genotypes" rel="noreferrer noopener">treat</a> adults with chronic (lasting a long time) hepatitis C virus (hep C) genotypes 1, 2, 3, 4, 5, or 6 infections without cirrhosis or with compensated cirrhosis.
In 2019, the FDA approved Mavyret to shorten the once-daily treatment duration from 12 to 8 weeks in treatment-naïve, compensated cirrhotic, chronic hepatitis C (HCV) patients across all genotypes (GT1-6).
Price Action: ABBV stock is trading higher by 1.54% to $192.43 at last check Wednesday.
Read Next:
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/general/biotech/25/03/44202109/atea-pharma-cuts-workforce-by-25-expects-15-million-in-cost-savings-plans-phase-3-hepatitis-c-trial" target="_blank" rel="noreferrer noopener">Atea Pharma Cuts Workforce By 25%, Expects $15 Million In Cost Savings, Plans Phase 3 Hepatitis C Trial</a></li>
</ul>
Photo by Tada Images via Shutterstock

Biotech

Large Cap

News

Health Care

General

ABBV

ENTA

FDA Expands AbbVie's Mavyret Label To Include Acute Hepatitis C Treatment (CORRECTED)

WIIM

Enanta Pharmaceuticals shares are trading higher after JMP Securities maintained an Outperform rating on the stock and raised its price target from $23 to $24.

JMP Securities analyst Roy Buchanan maintains Enanta Pharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ENTA#NASDAQ">ENTA</a>) with a Market Outperform and raises the price target from $23 to $24.

Price Target

Analyst Ratings

JMP Securities Maintains Market Outperform on Enanta Pharma, Raises Price Target to $24

<a href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.enanta.com%2F&amp;esheet=54258634&amp;newsitemid=20250522937132&amp;lan=en-US&amp;anchor=Enanta+Pharmaceuticals%2C+Inc.&amp;index=1&amp;md5=5b94d70ee258ae97e4fbe9842247f4ab">Enanta Pharmaceuticals, Inc.</a> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ENTA#NASDAQ">ENTA</a>), a clinical-stage biotechnology company dedicated to creating small molecule drugs for viral infections and immunological diseases, today announced that data from the Company's Phase 2 study of zelicapavir in young children infected with respiratory syncytial virus (RSV) will be available as an E-Poster at the 43rd Annual Meeting of the European Society for Paediatric Infectious Diseases (ESPID) 2025, being held May 26-30, 2025 at the Bucharest International Conference Centre in Bucharest, Romania and online.
The E-Poster will highlight results from a Phase 2 study of zelicapavir, an oral, non-nucleoside small-molecule RSV-replication-inhibitor (N-protein), which were announced in December 2024, and include new data on the population PK/PD and time to viral load negativity.

Enanta Pharma To Present Data From Phase 2 Study Of Zelicapavir In Children With Respiratory Syncytial Virus At 43rd Annual ESPID Meeting

Enanta Pharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ENTA#NASDAQ">ENTA</a>) reported quarterly losses of $(1.06) per share which beat the analyst consensus estimate of $(1.14) by 7.02 percent. This is a 27.89 percent increase over losses of $(1.47) per share from the same period last year. The company reported quarterly sales of $14.93 million which missed the analyst consensus estimate of $15.95 million by 6.43 percent. This is a 12.48 percent decrease over sales of $17.05 million the same period last year.

Earnings

Earnings Beats

Earnings Misses

Enanta Pharma Q2 EPS $(1.06) Beats $(1.14) Estimate, Sales $14.93M Miss $15.95M Estimate

&nbsp;Enanta's Phase 2a Study of EDP-323 Shows Reduced Mucus and Faster Viral Clearance in RSV-Infected Adults

Enanta Highlights RSV Polymerase Inhibitor Data At ESCMID 2025 In Vienna

<h3>Gainers</h3>
<ul>
<li>Lipella Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LIPO#NASDAQ">LIPO</a>) stock moved upwards by 49.5% to $4.56 during Tuesday's pre-market session. The market value of their outstanding shares is at $5.5 million. </li>
<li>IN8bio (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/INAB#NASDAQ">INAB</a>) shares increased by 49.46% to $0.4. The company's market cap stands at $29.2 million. </li>
<li>Ocean Biomedical (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OCEA#NASDAQ">OCEA</a>) stock rose 38.58% to $0.21. The company's market cap stands at $7.1 million. </li>
<li>Firefly Neuroscience (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AIFF#NASDAQ">AIFF</a>) stock rose 38.06% to $4.28. The market value of their outstanding shares is at $34.2 million. </li>
<li>Travere Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TVTX#NASDAQ">TVTX</a>) stock rose 16.35% to $24.55. The company's market cap stands at $2.1 billion. </li>
<li>Enanta Pharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ENTA#NASDAQ">ENTA</a>) shares increased by 13.06% to $5.54. The company's market cap stands at $118.1 million. As per the press release, Q1 earnings came out yesterday. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>T2 Biosystems (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TTOO#NASDAQ">TTOO</a>) shares declined by 43.4% to $0.11 during Tuesday's pre-market session. The market value of their outstanding shares is at $3.0 million. </li>
<li>Third Harmonic Bio (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/THRD#NASDAQ">THRD</a>) shares fell 29.25% to $3.29. The company's market cap stands at $148.2 million. </li>
<li>Aspira Womens Health (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AWH#NASDAQ">AWH</a>) stock declined by 26.7% to $0.26. The company's market cap stands at $4.4 million. </li>
<li>vTv Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VTVT#NASDAQ">VTVT</a>) shares declined by 18.97% to $15.0. The market value of their outstanding shares is at $39.1 million. </li>
<li>Lixte Biotechnology (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LIXT#NASDAQ">LIXT</a>) stock fell 17.54% to $1.88. The company's market cap stands at $4.2 million. </li>
<li>Hyperfine (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HYPR#NASDAQ">HYPR</a>) stock decreased by 16.77% to $1.39. The company's market cap stands at $101.3 million. 
See Also: <a href="http://www.benzinga.com/money/best-healthcare-stocks/" title="www.benzinga.com/money/best-healthcare-stocks/">www.benzinga.com/money/best-healthcare-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Movers

AIFF

HYPR

INAB

LIPO

LIXT

OCEA

THRD

TTOO

TVTX

VTVT

12 Health Care Stocks Moving In Tuesday's Pre-Market Session

JMP Securities analyst Roy Buchanan reiterates Enanta Pharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ENTA#NASDAQ">ENTA</a>) with a Market Outperform and maintains $21 price target.

Reiteration

JMP Securities Reiterates Market Outperform on Enanta Pharma, Maintains $21 Price Target

Enanta Pharmaceuticals shares are trading higher after the company reported Q1 financial results and beat its EPS estimate.

Providing a diverse range of perspectives from bullish to bearish, 4 analysts have published ratings on Enanta Pharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ENTA#NASDAQ">ENTA</a>) in the last three months.
The table below provides a snapshot of their recent ratings, showcasing how sentiments have evolved over the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">2</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">0</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
Providing deeper insights, analysts have established 12-month price targets, indicating an average target of $19.25, along with a high estimate of $21.00 and a low estimate of $18.00. Experiencing a 17.2% decline, the current average is now lower than the previous average price target of $23.25. 
<img src="https://www.benzinga.com/files/images/story/2025/1739278812_0_0.png" alt="price target chart" />
<h2>Breaking Down Analyst Ratings: A Detailed Examination</h2>
The perception of Enanta Pharma by financial experts is analyzed through recent analyst actions. The following summary presents key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Ed Arce</td>
<td>HC Wainwright &amp; Co.</td>
<td>Maintains</td>
<td>Buy</td>
<td>$18.00</td>
<td>$18.00</td>
</tr>
<tr>
<td>Ed Arce</td>
<td>HC Wainwright &amp; Co.</td>
<td>Lowers</td>
<td>Buy</td>
<td>$18.00</td>
<td>$27.00</td>
</tr>
<tr>
<td>Brian Skorney</td>
<td>Baird</td>
<td>Lowers</td>
<td>Outperform</td>
<td>$20.00</td>
<td>$26.00</td>
</tr>
<tr>
<td>Roy Buchanan</td>
<td>JMP Securities</td>
<td>Lowers</td>
<td>Market Outperform</td>
<td>$21.00</td>
<td>$22.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: In response to dynamic market conditions and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their reaction to recent developments related to Enanta Pharma. This insight gives a snapshot of analysts' perspectives on the current state of the company.</li>
<li>Rating: Analyzing trends, analysts offer qualitative evaluations, ranging from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of Enanta Pharma compared to the broader market.</li>
<li>Price Targets: Understanding forecasts, analysts offer estimates for Enanta Pharma's future value. Examining the current and prior targets provides insight into analysts' changing expectations.</li>
</ul>
Navigating through these analyst evaluations alongside other financial indicators can contribute to a holistic understanding of Enanta Pharma's market standing. Stay informed and make data-driven decisions with our Ratings Table.
<a href="https://www.benzinga.com/quote/ENTA/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on Enanta Pharma analyst ratings.</a>
If you are interested in following small-cap stock news and performance <a href="https://www.benzinga.com/news/small-cap">you can start by tracking it here</a>.
<h2>All You Need to Know About Enanta Pharma</h2>
Enanta Pharmaceuticals Inc is an American biotechnology company which uses robust, chemistry-driven approach and drug discovery capabilities to focus on the research and development of molecule drugs to cure viral infections and liver diseases. Uses virology and immunology method for curing the diseases. The targeted diseases are hepatitis C, hepatitis B, nonalcoholic steatohepatitis, and the respiratory syncytial virus. The novelty of company research is a specific direct-acting antiviral inhibitor against the hepatitis C virus. The company's inhibitors have been developed in collaboration with AbbVie. AbbVie markets the protease inhibitor, paritaprevir, while other inhibitors are in the pipeline.
<h3>Financial Milestones: Enanta Pharma's Journey</h3>
Market Capitalization Perspectives: The company's market capitalization falls below industry averages, signaling a relatively smaller size compared to peers. This positioning may be influenced by factors such as perceived growth potential or operational scale.
Revenue Growth: Enanta Pharma's revenue growth over a period of 3 months has faced challenges. As of 30 September, 2024, the company experienced a revenue decline of approximately -22.84%. This indicates a decrease in the company's top-line earnings. When compared to others in the Health Care sector, the company excelled with a growth rate higher than the average among peers.
Net Margin: Enanta Pharma's financial strength is reflected in its exceptional net margin, which exceeds industry averages. With a remarkable net margin of -197.32%, the company showcases strong profitability and effective cost management.
Return on Equity (ROE): Enanta Pharma's ROE falls below industry averages, indicating challenges in efficiently using equity capital. With an ROE of -20.76%, the company may face hurdles in generating optimal returns for shareholders.
Return on Assets (ROA): Enanta Pharma's financial strength is reflected in its exceptional ROA, which exceeds industry averages. With a remarkable ROA of -7.43%, the company showcases efficient use of assets and strong financial health.
Debt Management: Enanta Pharma's debt-to-equity ratio is notably higher than the industry average. With a ratio of 0.43, the company relies more heavily on borrowed funds, indicating a higher level of financial risk.
<h2>Analyst Ratings: Simplified</h2>
Experts in banking and financial systems, analysts specialize in reporting for specific stocks or defined sectors. Their comprehensive research involves attending company conference calls and meetings, analyzing financial statements, and engaging with insiders to generate what are known as analyst ratings for stocks. Typically, analysts assess and rate each stock once per quarter.
Some analysts publish their predictions for metrics such as growth estimates, earnings, and revenue to provide additional guidance with their ratings. When using analyst ratings, it is important to keep in mind that stock and sector analysts are also human and are only offering their opinions to investors.
If you want to keep track of which analysts are outperforming others, you can view updated analyst ratings along withanalyst success scores in <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a>.
Breaking: Wall Street's Next Big Mover
Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. <a href="https://www.benzinga.com/premium/ideas/turning-point-trader-checkout-2/?t=Tu1tu3arja3be22tu36&amp;utm_source=benzinga-insights">Click here for urgent details</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

The Analyst Verdict: Enanta Pharma In The Eyes Of 4 Experts

HC Wainwright &amp; Co. analyst Ed Arce reiterates Enanta Pharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ENTA#NASDAQ">ENTA</a>) with a Buy and maintains $18 price target.

HC Wainwright & Co. Reiterates Buy on Enanta Pharma, Maintains $18 Price Target

Enanta Pharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ENTA#NASDAQ">ENTA</a>) reported quarterly losses of $(1.05) per share which beat the analyst consensus estimate of $(1.35) by 22.22 percent. This is a 33.54 percent increase over losses of $(1.58) per share from the same period last year. The company reported quarterly sales of $16.96 million which missed the analyst consensus estimate of $17.25 million by 1.68 percent. This is a 5.80 percent decrease over sales of $18.00 million the same period last year.

Enanta Pharma Q1 EPS $(1.05) Beats $(1.35) Estimate, Sales $16.96M Miss $17.25M Estimate

<h3>Gainers</h3>
<ul>
<li>Biomerica (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BMRA#NASDAQ">BMRA</a>) shares rose 222.8% to $1.13 during Thursday's pre-market session. The market value of their outstanding shares is at $19.0 million. As per the news, the Q2 earnings report came out 2 days ago. </li>
<li>Aditxt (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ADTX#NASDAQ">ADTX</a>) stock moved upwards by 53.51% to $0.2. The company's market cap stands at $2.8 million. </li>
<li>Surrozen (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SRZN#NASDAQ">SRZN</a>) shares increased by 20.84% to $14.32. The market value of their outstanding shares is at $46.5 million. </li>
<li>Traws Pharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TRAW#NASDAQ">TRAW</a>) shares increased by 13.78% to $7.8. The company's market cap stands at $23.5 million. </li>
<li>Aclarion (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ACON#NASDAQ">ACON</a>) shares moved upwards by 12.0% to $0.05. </li>
<li>Enanta Pharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ENTA#NASDAQ">ENTA</a>) shares rose 10.05% to $5.3. The company's market cap stands at $112.4 million. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>Atara Biotherapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ATRA#NASDAQ">ATRA</a>) stock decreased by 50.5% to $6.52 during Thursday's pre-market session. The market value of their outstanding shares is at $37.5 million. </li>
<li>Silexion Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SLXN#NASDAQ">SLXN</a>) shares fell 21.8% to $1.22. The company's market cap stands at $1.9 million. </li>
<li>GlucoTrack (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GCTK#NASDAQ">GCTK</a>) stock decreased by 14.56% to $0.07. The market value of their outstanding shares is at $1.0 million. </li>
<li>ArriVent BioPharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AVBP#NASDAQ">AVBP</a>) stock fell 11.68% to $22.01. The company's market cap stands at $741.6 million. </li>
<li>Helius Medical Tech (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HSDT#NASDAQ">HSDT</a>) shares fell 10.95% to $0.76. The market value of their outstanding shares is at $2.8 million. </li>
<li>Tenax Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TENX#NASDAQ">TENX</a>) stock fell 10.5% to $5.8. The market value of their outstanding shares is at $19.7 million. 
See Also: <a href="http://www.benzinga.com/money/best-healthcare-stocks/" title="www.benzinga.com/money/best-healthcare-stocks/">www.benzinga.com/money/best-healthcare-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

ACON

ADTX

ATRA

AVBP

BMRA

GCTK

HSDT

SLXN

SRZN

TENX

TRAW

12 Health Care Stocks Moving In Thursday's Pre-Market Session

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our <a href="https://www.benzinga.com/analyst-stock-ratings">analyst ratings page</a>.
<ul>
<li>Northland Capital Markets cut the price target for Applied Optoelectronics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AAOI#NASDAQ">AAOI</a>) from $20 to $18. Northland Capital Markets analyst Tim Savageaux maintained an Outperform rating. <a href="https://www.benzinga.com/quote/AAOI/analyst-ratings">Applied Optoelectronics shares closed at $37.74 on Friday. See how other analysts view this stock.</a></li>
<li>HC Wainwright &amp; Co. raised BigBear.ai Holdings, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BBAI#NYSE">BBAI</a>) price target from $3 to $7. HC Wainwright &amp; Co. analyst Scott Buck maintained a Buy rating. BigBear.ai shares closed at $4.21 on Friday. See how other analysts view this stock.</li>
<li>Baird slashed the price target for Polaris Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PII#NYSE">PII</a>) from $84 to $72. Baird analyst Craig Kennison maintained an Outperform rating. Polaris shares closed at $57.43 on Friday. <a href="https://www.benzinga.com/quote/PII/analyst-ratings">See how other analysts view this stock.</a></li>
<li>Raymond James raised the price target for Allegiant Travel Company (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ALGT#NASDAQ">ALGT</a>) from $75 to $110. Raymond James analyst Savanthi Syth maintained an Outperform rating. Allegiant Travel shares closed at $91.11 on Friday. See how other analysts view this stock.</li>
<li>Raymond James boosted SkyWest, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SKYW#NASDAQ">SKYW</a>) price target from $114 to $120. Raymond James analyst Savanthi Syth maintained an Outperform rating. SkyWest shares settled at $101.26 on Friday. <a href="https://www.benzinga.com/quote/SKYW/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Raymond James increased United Airlines Holdings, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/UAL#NASDAQ">UAL</a>) price target from $90 to $120. Raymond James analyst Savanthi Syth maintained an Outperform rating. United Airlines shares closed at $99.65 on Friday. <a href="https://www.benzinga.com/quote/MSFT/analyst-ratings">See how other analysts view this stock.</a></li>
<li>Raymond James raised Southwest Airlines Co. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LUV#NYSE">LUV</a>) price target from $36 to $40. Raymond James analyst Savanthi Syth maintained an Outperform rating. Southwest shares closed at $34.04 on Friday.  <a href="https://www.benzinga.com/quote/LUV/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Northland Capital Markets raised the price target for Ondas Holdings Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ONDS#NASDAQ">ONDS</a>) from $1.5 to $4. Northland Capital Markets analyst Michael Latimore maintained an Outperform rating. Ondas Holdings shares settled at $2.59 on Friday. <a href="https://www.benzinga.com/quote/ONDS/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Lake Street cut TechTarget, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TTGT#NASDAQ">TTGT</a>) price target from $36 to $24. Lake Street analyst Eric Martinuzzi maintained a Buy rating. TechTarget shares closed at $19.48 on Monday. <a href="https://www.benzinga.com/quote/TTGT/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>HC Wainwright &amp; Co. cut Enanta Pharmaceuticals, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ENTA#NASDAQ">ENTA</a>) price target from $27 to $18. HC Wainwright &amp; Co. analyst Ed Arce maintained a Buy rating. Enanta Pharmaceuticals shares closed at $6.37 on Monday. <a href="https://www.benzinga.com/quote/MSFT/analyst-ratings">See how other analysts view this stock</a>.</li>
</ul>
Read This Next: 
<ul>
<li><a href="https://www.benzinga.com/24/12/42700627/how-to-earn-500-a-month-from-rpm-international-stock-ahead-of-q2-earnings">How To Earn $500 A Month From RPM International Stock Ahead Of Q2 Earnings</a></li>
</ul>

Markets

Trading Ideas

AAOI

ALGT

BBAI

ONDS

SKYW

TTGT

United Airlines To Rally More Than 20%? Here Are Top Analyst Forecasts For Monday

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our <a href="https://www.benzinga.com/analyst-stock-ratings">analyst ratings page</a>.
<ul>
<li>DA Davidson cut Winnebago Industries, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/WGO#NYSE">WGO</a>) price target from $55 to $54. DA Davidson analyst Brandon Rolle maintained a Neutral rating. Winnebago shares closed at $47.99 on Monday. See how other analysts view this stock.</li>
<li>Evercore ISI Group cut the price target for Regency Centers Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/REG#NASDAQ">REG</a>) from $78 to $77. Evercore ISI Group analyst Steve Sakwa maintained an In-Line rating. Regency Centers shares closed at $73.75 on Monday. See how other analysts view this stock.</li>
<li>Telsey Advisory Group lowered the price target for Nordstrom, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/JWN#NYSE">JWN</a>) from $26 to $24. Telsey Advisory Group analyst Dana Telsey maintained a Market Perform rating. Nordstrom shares closed at $24.17 on Monday. <a href="https://www.benzinga.com/quote/MSFT/analyst-ratings">See how other analysts view this stock.</a></li>
<li>HC Wainwright &amp; Co. boosted the price target for BTCS Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BTCS#NASDAQ">BTCS</a>) from $3 to $5. HC Wainwright &amp; Co. analyst Kevin Dede maintained a Buy rating. BTCS shares closed at $2.47 on Monday. <a href="https://www.benzinga.com/quote/MSFT/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Goldman Sachs boosted CrowdStrike Holdings, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CRWD#NASDAQ">CRWD</a>) price target from $372 to $415. Goldman Sachs analyst Gabriela Borges maintained a Buy rating. CrowdStrike shares settled at $361.50 on Monday. <a href="https://www.benzinga.com/quote/MSFT/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Evercore ISI Group cut Brixmor Property Group Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BRX#NYSE">BRX</a>) price target from $32 to $31. Evercore ISI Group analyst Samir Khanal maintained an In-Line rating. Brixmor Property shares closed at $27.53 on Monday. <a href="https://www.benzinga.com/quote/MSFT/analyst-ratings">See how other analysts view this stock.</a></li>
<li>DA Davidson slashed Destination XL Group, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DXLG#NASDAQ">DXLG</a>) price target from $3.5 to $3. DA Davidson analyst Michael Baker maintained a Buy rating. Destination XL shares closed at $2.61 on Monday.  <a href="https://www.benzinga.com/quote/MSFT/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Keefe, Bruyette &amp; Woods raised the price target for Berkshire Hills Bancorp, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BHLB#NYSE">BHLB</a>) from $32 to $34.5. Keefe, Bruyette &amp; Woods analyst Christopher O&#8217;Connell maintained a Market Perform rating. Berkshire Hills Bancorp shares settled at $28.60 on Monday. <a href="https://www.benzinga.com/quote/MSFT/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>B. Riley Securities cut OptimizeRx Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OPRX#NASDAQ">OPRX</a>) price target from $17 to $13. B. Riley Securities analyst Neil Chatterji maintained a Buy rating. OptimizeRx shares closed at $4.83 on Monday. <a href="https://www.benzinga.com/quote/MSFT/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>HC Wainwright &amp; Co. cut Enanta Pharmaceuticals, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ENTA#NASDAQ">ENTA</a>) price target from $27 to $18. HC Wainwright &amp; Co. analyst Ed Arce maintained a Buy rating. Enanta Pharmaceuticals shares closed at $6.37 on Monday. <a href="https://www.benzinga.com/quote/MSFT/analyst-ratings">See how other analysts view this stock</a>.</li>
</ul>
Read This Next: 
<ul>
<li><a href="https://www.benzinga.com/trading-ideas/long-ideas/24/12/42648003/how-to-earn-500-a-month-from-qualcomm-stock-2">How To Earn $500 A Month From Qualcomm Stock</a></li>
</ul>

BHLB

BTCS

CRWD

DXLG

OPRX

CrowdStrike To Rally Around 15%? Here Are 10 Top Analyst Forecasts For Tuesday

<a href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.enanta.com%2F&amp;esheet=54170813&amp;newsitemid=20241224565771&amp;lan=en-US&amp;anchor=Enanta+Pharmaceuticals%2C+Inc&amp;index=1&amp;md5=c412227958438d701e3e355f86717b04">Enanta Pharmaceuticals, Inc</a>. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ENTA#NASDAQ">ENTA</a>), a clinical-stage biotechnology company dedicated to creating small molecule drugs for virology and immunology indications, today announced that the United States District Court of Massachusetts ("the Court") has issued a ruling on a summary judgment motion filed by Pfizer, Inc. in connection with Enanta's patent infringement lawsuit seeking damages for infringement of U.S. Patent No. 11,358,953 ("the '953 Patent") in the manufacture, use and sale of Pfizer's COVID-19 antiviral, Paxlovid&#x2122; (nirmatrelvir tablets; ritonavir tablets).
The Court issued a summary judgment decision granting Pfizer's motion that the ‘953 Patent is invalid. In its decision, the Court also denied Enanta's partial motion for summary judgment of infringement as moot in light of its allowance of summary judgment on invalidity. Enanta plans to appeal the decision to the Court of Appeals for the Federal Circuit.

Government

Regulations

Legal

Court Rules Enanta Patent Invalid in Pfizer Paxlovid Case; Appeal Planned

Providing a diverse range of perspectives from bullish to bearish, 6 analysts have published ratings on Enanta Pharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ENTA#NASDAQ">ENTA</a>) in the last three months.
The following table provides a quick overview of their recent ratings, highlighting the changing sentiments over the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">2</td>
<td align="right">4</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">0</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">1</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
Insights from analysts' 12-month price targets are revealed, presenting an average target of $21.67, a high estimate of $27.00, and a low estimate of $18.00. This current average has decreased by 10.93% from the previous average price target of $24.33. 
<img src="https://www.benzinga.com/files/images/story/2024/1735041636_0.png" alt="price target chart" />
<h2>Decoding Analyst Ratings: A Detailed Look</h2>
In examining recent analyst actions, we gain insights into how financial experts perceive Enanta Pharma. The following summary outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Ed Arce</td>
<td>HC Wainwright &amp; Co.</td>
<td>Lowers</td>
<td>Buy</td>
<td>$18.00</td>
<td>$27.00</td>
</tr>
<tr>
<td>Brian Skorney</td>
<td>Baird</td>
<td>Lowers</td>
<td>Outperform</td>
<td>$20.00</td>
<td>$26.00</td>
</tr>
<tr>
<td>Roy Buchanan</td>
<td>JMP Securities</td>
<td>Lowers</td>
<td>Market Outperform</td>
<td>$21.00</td>
<td>$22.00</td>
</tr>
<tr>
<td>Ed Arce</td>
<td>HC Wainwright &amp; Co.</td>
<td>Maintains</td>
<td>Buy</td>
<td>$27.00</td>
<td>$27.00</td>
</tr>
<tr>
<td>Roy Buchanan</td>
<td>JMP Securities</td>
<td>Maintains</td>
<td>Market Outperform</td>
<td>$22.00</td>
<td>$22.00</td>
</tr>
<tr>
<td>Roy Buchanan</td>
<td>JMP Securities</td>
<td>Maintains</td>
<td>Market Outperform</td>
<td>$22.00</td>
<td>$22.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts adapt their recommendations to changing market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their response to recent developments related to Enanta Pharma. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Delving into assessments, analysts assign qualitative values, from 'Outperform' to 'Underperform'. These ratings communicate expectations for the relative performance of Enanta Pharma compared to the broader market.</li>
<li>Price Targets: Analysts predict movements in price targets, offering estimates for Enanta Pharma's future value. Examining the current and prior targets offers insights into analysts' evolving expectations.</li>
</ul>
To gain a panoramic view of Enanta Pharma's market performance, explore these analyst evaluations alongside essential financial indicators. Stay informed and make judicious decisions using our Ratings Table.
<a href="https://www.benzinga.com/quote/ENTA/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on Enanta Pharma analyst ratings.</a>
If you are interested in following small-cap stock news and performance <a href="https://www.benzinga.com/news/small-cap">you can start by tracking it here</a>.
<h2>Get to Know Enanta Pharma Better</h2>
Enanta Pharmaceuticals Inc is an American biotechnology company which uses robust, chemistry-driven approach and drug discovery capabilities to focus on the research and development of molecule drugs to cure viral infections and liver diseases. Uses virology and immunology method for curing the diseases. The targeted diseases are hepatitis C, hepatitis B, nonalcoholic steatohepatitis, and the respiratory syncytial virus. The novelty of company research is a specific direct-acting antiviral inhibitor against the hepatitis C virus. The company's inhibitors have been developed in collaboration with AbbVie. AbbVie markets the protease inhibitor, paritaprevir, while other inhibitors are in the pipeline.
<h3>Financial Insights: Enanta Pharma</h3>
Market Capitalization: Indicating a reduced size compared to industry averages, the company's market capitalization poses unique challenges.
Decline in Revenue: Over the 3 months period, Enanta Pharma faced challenges, resulting in a decline of approximately -22.84% in revenue growth as of 30 September, 2024. This signifies a reduction in the company's top-line earnings. In comparison to its industry peers, the company trails behind with a growth rate lower than the average among peers in the Health Care sector.
Net Margin: Enanta Pharma's net margin excels beyond industry benchmarks, reaching -197.32%. This signifies efficient cost management and strong financial health.
Return on Equity (ROE): Enanta Pharma's ROE lags behind industry averages, suggesting challenges in maximizing returns on equity capital. With an ROE of -20.76%, the company may face hurdles in achieving optimal financial performance.
Return on Assets (ROA): Enanta Pharma's ROA is below industry averages, indicating potential challenges in efficiently utilizing assets. With an ROA of -7.43%, the company may face hurdles in achieving optimal financial returns.
Debt Management: The company faces challenges in debt management with a debt-to-equity ratio higher than the industry average. With a ratio of 0.43, caution is advised due to increased financial risk.
<h2>The Significance of Analyst Ratings Explained</h2>
Analyst ratings serve as essential indicators of stock performance, provided by experts in banking and financial systems. These specialists diligently analyze company financial statements, participate in conference calls, and engage with insiders to generate quarterly ratings for individual stocks.
Some analysts will also offer forecasts for metrics like growth estimates, earnings, and revenue to provide further guidance on stocks. Investors who use analyst ratings should note that this specialized advice comes from humans and may be subject to error.
Breaking: Wall Street's Next Big Mover
Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. <a href="https://www.benzinga.com/premium/ideas/turning-point-trader-checkout-2/?t=Tu1tu3arja3be22tu36&amp;utm_source=benzinga-insights">Click here for urgent details</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Enanta Pharma Stock: A Deep Dive Into Analyst Perspectives (6 Ratings)

HC Wainwright &amp; Co. analyst Ed Arce maintains Enanta Pharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ENTA#NASDAQ">ENTA</a>) with a Buy and lowers the price target from $27 to $18.

HC Wainwright & Co. Maintains Buy on Enanta Pharma, Lowers Price Target to $18

<ul>
<li>Observed an antiviral effect for the primary and secondary virology endpoints in the overall population, with a viral load decline of 1.4 log at the end of treatment in Part 2</li>
<li>Demonstrated a viral load decline of 1.2 log compared to placebo at the end of treatment in prespecified analysis of patients randomized within 3 days of symptom onset</li>
<li>Zelicapavir was well-tolerated with a favorable safety profile</li>
</ul>

Enanta Pharmaceuticals Announced Topline Results From The First-in-pediatrics Phase 2 Study Evaluating Zelicapavir Children Aged 28 Days To 36 Months With Respiratory Syncytial Virus, Showing Antiviral Effect For The Primary And Secondary Virology Endpoints In The Overall Pooled Efficacy Population

<ul>
<li>Conference call and webcast to discuss data on Monday, December 9 at 8:30 a.m. ET</li>
</ul>
<a href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.enanta.com&amp;esheet=54163368&amp;newsitemid=20241206627146&amp;lan=en-US&amp;anchor=Enanta+Pharmaceuticals%2C+Inc.&amp;index=1&amp;md5=20d384e13292c32afa00e9dd99c15466">Enanta Pharmaceuticals, Inc.</a> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ENTA#NASDAQ">ENTA</a>), a clinical-stage biotechnology company dedicated to creating small molecule drugs for virology and immunology indications, today announced the company will hold a conference call and webcast on Monday, December 9 at 8:30 a.m. ET to share topline results from RSVPEDs, a first-in-pediatrics Phase 2 study evaluating zelicapavir in hospitalized and non-hospitalized children aged 28 days to 36 months with respiratory syncytial virus (RSV).

Enanta Pharmaceuticals To Present Topline Results From Its Phase 2 Study Evaluating Zelicapavir For Respiratory Syncytial Virus; Conference Call And Webcast To Discuss Data On Monday, December 9 At 8:30 a.m. ET

Press Releases

Enanta Pharmaceuticals to Appeal Ruling Related to '953 Patent Infringement Lawsuit

Enanta Pharmaceuticals to Present at the 43rd Annual J.P. Morgan Healthcare Conference

Enanta Pharmaceuticals Reports Financial Results for its Fiscal First Quarter Ended December 31, 2024

Enanta Pharmaceuticals to Present Data for its Respiratory Syncytial Virus Program at the 13th International RSV Symposium

Enanta Pharmaceuticals to Present at the H.C. Wainwright 3rd Annual Autoimmune & Inflammatory Disease Virtual Conference

Enanta Pharmaceuticals Announces Respiratory Syncytial Virus Data Presentation at ESCMID Global 2025

Enanta Pharmaceuticals Reports Financial Results for its Fiscal Second Quarter Ended March 31, 2025

Enanta Pharmaceuticals Announces Data from its Phase 2 Study of Zelicapavir in Children with Respiratory Syncytial Virus to be Presented at the 43rd Annual ESPID Meeting

Enanta Pharmaceuticals to Present at the Jefferies Global Healthcare Conference

Enanta Pharmaceuticals' Partner AbbVie Receives U.S. FDA Approval of an Expanded Indication for MAVYRET® (glecaprevir/pibrentasvir) as the First and Only Treatment for People with Acute Hepatitis C Virus

Comments

Enanta Pharma

Enanta Pharma (ENTA) Options

Enanta Pharma (NASDAQ:ENTA) Stock, Chaîne d'Options

Notizie

PARTENAIRE / CONTRIBUTEUR

BENZINGA MONDIAL